NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

急性冠狀動脈症候群的全球市場

Acute Coronary Syndrome

出版商 Global Industry Analysts, Inc. 商品編碼 997864
出版日期 內容資訊 英文 156 Pages
商品交期: 最快1-2個工作天內
價格
急性冠狀動脈症候群的全球市場 Acute Coronary Syndrome
出版日期: 2021年04月01日內容資訊: 英文 156 Pages
簡介

全球急性冠狀動脈症候群的市場規模,預計在分析期間(2020年∼2027年)將以12.2%的年複合成長率增長,從2020年的303億美元,到2027年達到677億美元。

本報告提供全球急性冠狀動脈症候群市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:60公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6355

Abstract:

Global Acute Coronary Syndrome Market to Reach $67.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Acute Coronary Syndrome estimated at US$30.3 Billion in the year 2020, is projected to reach a revised size of US$67.7 Billion by 2027, growing at a CAGR of 12.2% over the period 2020-2027.

The U.S. Market is Estimated at $8.2 Billion, While China is Forecast to Grow at 16% CAGR

The Acute Coronary Syndrome market in the U.S. is estimated at US$8.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.8 Billion by the year 2027 trailing a CAGR of 16% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.6% and 10.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Select Competitors (Total 60 Featured) -

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 4: USA Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 5: USA Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • CANADA
    • TABLE 6: Canada Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 7: Canada Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • JAPAN
    • TABLE 8: Japan Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 9: Japan Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • CHINA
    • TABLE 10: China Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 11: China Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • EUROPE
    • TABLE 12: Europe Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 13: Europe Historic Review for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 14: Europe 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 15: France Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 16: France Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • GERMANY
    • TABLE 17: Germany Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 18: Germany Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ITALY
    • TABLE 19: Italy Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: Italy Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • UNITED KINGDOM
    • TABLE 21: UK Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 22: UK Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • SPAIN
    • TABLE 23: Spain Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Spain Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • RUSSIA
    • TABLE 25: Russia Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Russia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF EUROPE
    • TABLE 27: Rest of Europe Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Rest of Europe Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ASIA-PACIFIC
    • TABLE 29: Asia-Pacific Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 30: Asia-Pacific Historic Review for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 31: Asia-Pacific 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 32: Australia Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 33: Australia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • INDIA
    • TABLE 34: India Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: India Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • SOUTH KOREA
    • TABLE 36: South Korea Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 37: South Korea Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 38: Rest of Asia-Pacific Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 39: Rest of Asia-Pacific Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • LATIN AMERICA
    • TABLE 40: Latin America Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 41: Latin America Historic Review for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Latin America 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 43: Argentina Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Argentina Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • BRAZIL
    • TABLE 45: Brazil Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Brazil Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • MEXICO
    • TABLE 47: Mexico Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 48: Mexico Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 49: Rest of Latin America Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Rest of Latin America Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • MIDDLE EAST
    • TABLE 51: Middle East Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 52: Middle East Historic Review for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 53: Middle East 15-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
  • IRAN
    • TABLE 54: Iran Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 55: Iran Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • ISRAEL
    • TABLE 56: Israel Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 57: Israel Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • SAUDI ARABIA
    • TABLE 58: Saudi Arabia Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Saudi Arabia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 60: UAE Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 61: UAE Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 62: Rest of Middle East Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 63: Rest of Middle East Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • AFRICA
    • TABLE 64: Africa Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Africa Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR

IV. COMPETITION

  • Total Companies Profiled: 60